Skip to main content
The BMJ logoLink to The BMJ
. 1993 May 15;306(6888):1293–1296. doi: 10.1136/bmj.306.6888.1293

Transurethral microwave treatment for benign prostatic hypertrophy: a randomised controlled clinical trial.

A S Bdesha 1, C J Bunce 1, J P Kelleher 1, M E Snell 1, J Vukusic 1, R O Witherow 1
PMCID: PMC1677744  PMID: 7686065

Abstract

OBJECTIVES--To determine whether transurethral microwave treatment for patients with benign prostatic hypertrophy provides significant symptomatic relief, a reduction in residual urine volumes, and improvements in flow rates compared with sham treatment. DESIGN--Prospective double blind randomised study with follow up at three months. SETTING--Department of Urology in a London teaching hospital. PATIENTS--40 men completed the study: 22 received microwave treatment and 18 received sham treatment. Entry criteria were symptoms of prostatism of at least six months' duration, a total symptom score > 14, and a peak urine flow rate < 15 ml/s or a residual urine volume > 50 ml. Exclusion criteria were prostatic cancer, a residual urine volume > 200 ml, a very large prostate, an obstructing middle lobe, acute urinary retention, impaired renal function, coexisting urinary tract disease, and previous prostatic surgery. INTERVENTIONS--A single 90 minute transurethral microwave treatment or sham treatment. OUTCOME MEASURES--Patients' symptoms (including daytime frequency and nocturia) recorded in a self assessment symptom score questionnaire, peak urinary flow rates, and residual urine volumes. RESULTS--The mean total symptom scores of the patients who received microwave treatment fell from 30 to 11 compared with a fall from 31 to 26 for patients who received sham treatment (p < 0.001). Among patients who received microwave treatment daytime frequency fell from 9.4 to 5.5 voids a day and night time frequency from 3.5 to 1.6 voids a night; residual urine volumes fell from 104 ml to 52 ml; and peak urine flow rates increased by 2.3 ml/s. In the control group there was no improvement in any of these features. Treatment preserved sexual function and antegrade ejaculation. CONCLUSIONS--For selected patients with prostatism microwave treatment is effective and has few side effects.

Full text

PDF
1293

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baert O., Ameye F., Willemen P., Vandenhove J., Lauweryns J., Astrahan M., Petrovich Z. Transurethral microwave hyperthermia for benign prostatic hyperplasia: preliminary clinical and pathological results. J Urol. 1990 Dec;144(6):1383–1387. doi: 10.1016/s0022-5347(17)39748-3. [DOI] [PubMed] [Google Scholar]
  2. Berry S. J., Coffey D. S., Walsh P. C., Ewing L. L. The development of human benign prostatic hyperplasia with age. J Urol. 1984 Sep;132(3):474–479. doi: 10.1016/s0022-5347(17)49698-4. [DOI] [PubMed] [Google Scholar]
  3. Bosch R. J., Griffiths D. J., Blom J. H., Schroeder F. H. Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters. J Urol. 1989 Jan;141(1):68–72. doi: 10.1016/s0022-5347(17)40591-x. [DOI] [PubMed] [Google Scholar]
  4. Bruskewitz R. C., Larsen E. H., Madsen P. O., Dørflinger T. 3-year followup of urinary symptoms after transurethral resection of the prostate. J Urol. 1986 Sep;136(3):613–615. doi: 10.1016/s0022-5347(17)44991-3. [DOI] [PubMed] [Google Scholar]
  5. Chilton C. P., Morgan R. J., England H. R., Paris A. M., Blandy J. P. A critical evaluation of the results of transurethral resection of the prostate. Br J Urol. 1978 Dec;50(7):542–546. doi: 10.1111/j.1464-410x.1978.tb06208.x. [DOI] [PubMed] [Google Scholar]
  6. Fowler F. J., Jr, Wennberg J. E., Timothy R. P., Barry M. J., Mulley A. G., Jr, Hanley D. Symptom status and quality of life following prostatectomy. JAMA. 1988 May 27;259(20):3018–3022. [PubMed] [Google Scholar]
  7. Glynn R. J., Campion E. W., Bouchard G. R., Silbert J. E. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol. 1985 Jan;121(1):78–90. [PubMed] [Google Scholar]
  8. Kirby R. S., Bryan J., Eardley I., Christmas T. J., Liu S., Holmes S. A., Vale J. A., Shanmuganathan K., Webb J. A. Finasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation. Br J Urol. 1992 Jul;70(1):65–72. doi: 10.1111/j.1464-410x.1992.tb15666.x. [DOI] [PubMed] [Google Scholar]
  9. Klein L. A., Lemming B. Balloon dilatation for prostatic obstruction. Long-term follow-up. Urology. 1989 Mar;33(3):198–201. doi: 10.1016/0090-4295(89)90390-7. [DOI] [PubMed] [Google Scholar]
  10. Lytton B., Emery J. M., Harvard B. M. The incidence of benign prostatic obstruction. J Urol. 1968 May;99(5):639–645. doi: 10.1016/S0022-5347(17)62763-0. [DOI] [PubMed] [Google Scholar]
  11. Neal D. E., Ramsden P. D., Sharples L., Smith A., Powell P. H., Styles R. A., Webb R. J. Outcome of elective prostatectomy. BMJ. 1989 Sep 23;299(6702):762–767. doi: 10.1136/bmj.299.6702.762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Reddy P. K., Wasserman N., Castañeda F., Castañeda-Zuñiga W. R. Balloon dilatation of the prostate for treatment of benign hyperplasia. Urol Clin North Am. 1988 Aug;15(3):529–535. [PubMed] [Google Scholar]
  13. Sapozink M. D., Boyd S. D., Astrahan M. A., Jozsef G., Petrovich Z. Transurethral hyperthermia for benign prostatic hyperplasia: preliminary clinical results. J Urol. 1990 May;143(5):944–950. doi: 10.1016/s0022-5347(17)40146-7. [DOI] [PubMed] [Google Scholar]
  14. Servadio C., Leib Z., Lev A. Diseases of prostate treated by local microwave hyperthermia. Urology. 1987 Aug;30(2):97–99. doi: 10.1016/0090-4295(87)90169-5. [DOI] [PubMed] [Google Scholar]
  15. Stawarz B., Szmigielski S., Ogrodnik J., Astrahan M., Petrovich Z. A comparison of transurethral and transrectal microwave hyperthermia in poor surgical risk benign prostatic hyperplasia patients. J Urol. 1991 Aug;146(2):353–357. doi: 10.1016/s0022-5347(17)37792-3. [DOI] [PubMed] [Google Scholar]
  16. Vicente J., Salvador J., Chéchile G. Spiral urethral prosthesis as an alternative to surgery in high risk patients with benign prostatic hyperplasia: prospective study. J Urol. 1989 Dec;142(6):1504–1506. doi: 10.1016/s0022-5347(17)39140-1. [DOI] [PubMed] [Google Scholar]
  17. Wennberg J. E., Roos N., Sola L., Schori A., Jaffe R. Use of claims data systems to evaluate health care outcomes. Mortality and reoperation following prostatectomy. JAMA. 1987 Feb 20;257(7):933–936. [PubMed] [Google Scholar]
  18. Yerushalmi A., Fishelovitz Y., Singer D., Reiner I., Arielly J., Abramovici Y., Catsenelson R., Levy E., Shani A. Localized deep microwave hyperthermia in the treatment of poor operative risk patients with benign prostatic hyperplasia. J Urol. 1985 May;133(5):873–876. doi: 10.1016/s0022-5347(17)49270-6. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES